Saturday - May 4, 2024
Emergent BioSolutions, Mount Sinai Health System Announce Initiation of Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin Product Candidate for Prophylaxis
December 31, 2020
NEW YORK, Dec. 31 (TNSRes) -- The Mount Sinai Health System issued the following news release on Dec. 30:

Emergent BioSolutions (NYSE: EBS) and Mount Sinai Health System today announced initiation of the clinical program to evaluate Emergent's COVID-19 Human Hyperimmune Globulin (COVID-HIG) product candidate in the first of two Phase 1 studies to support its use for potential post-exposure prophylaxis in individuals at high risk of exposure to SARS-CoV-2, the virus that causes COVID . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products